Literature DB >> 9143857

Neuropsychiatric adverse effects of antiparkinsonian drugs. Characteristics, evaluation and treatment.

B K Young1, R Camicioli, L Ganzini.   

Abstract

Parkinson's disease (PD) is a progressive neurological condition that causes considerable disability in the elderly. Drugs used to treat PD, such as levodopa, offer symptomatic relief but often have neuropsychiatric adverse effects, most prominently psychosis and delirium. Aged patients and those with dementia are particularly vulnerable to these adverse effects. Evaluating PD patients with drug-induced neuropsychiatric adverse effects is made difficult by their complex clinical presentations. The treatment of drug-induced psychosis and delirium begins with manipulating the antiparkinsonian drug regimen, but this frequently worsens motor function. Atypical antipsychotics such as clozapine have been successfully employed to treat the psychosis without worsening the motor disability. Patient intolerance of clozapine therapy has prompted open-label studies with newer agents such as risperidone, remoxipride, zotepine, mianserin and ondansetron.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9143857     DOI: 10.2165/00002512-199710050-00005

Source DB:  PubMed          Journal:  Drugs Aging        ISSN: 1170-229X            Impact factor:   3.923


  139 in total

Review 1.  The management of the levodopa psychoses.

Authors:  J H Friedman
Journal:  Clin Neuropharmacol       Date:  1991-08       Impact factor: 1.592

2.  Anwesenheit: psychopathology and clinical associations.

Authors:  C Thompson
Journal:  Br J Psychiatry       Date:  1982-12       Impact factor: 9.319

3.  Treatment of drug-induced exogenous psychosis in parkinsonism with clozapine and fluperlapine.

Authors:  E Scholz; J Dichgans
Journal:  Eur Arch Psychiatry Neurol Sci       Date:  1985

4.  Levodopa's awakening effect on patients with Parkinsonism.

Authors:  G G Marsh; C M Markham; R Ansel
Journal:  J Neurol Neurosurg Psychiatry       Date:  1971-06       Impact factor: 10.154

5.  International guide to drugs for Parkinson's disease.

Authors:  W H Oertel; R C Dodel
Journal:  Mov Disord       Date:  1995-03       Impact factor: 10.338

6.  Fluctuations in plasma dopamine level impair memory in Parkinson's disease.

Authors:  S J Huber; H G Shulman; G W Paulson; E C Shuttleworth
Journal:  Neurology       Date:  1987-08       Impact factor: 9.910

7.  Symptomatic effect of selegiline in de novo Parkinsonian patients. The French Selegiline Multicenter Trial.

Authors:  H Allain; P Pollak; H C Neukirch
Journal:  Mov Disord       Date:  1993       Impact factor: 10.338

8.  Is L-DOPA drug holiday useful?

Authors:  L K Direnfeld; R G Feldman; M P Alexander; M Kelly-Hayes
Journal:  Neurology       Date:  1980-07       Impact factor: 9.910

9.  Psychotic complications of long-term levodopa treatment of Parkinson's disease.

Authors:  A Friedman; J Sienkiewicz
Journal:  Acta Neurol Scand       Date:  1991-08       Impact factor: 3.209

10.  Pharmacology of hallucinations induced by long-term drug therapy.

Authors:  C G Goetz; C M Tanner; H L Klawans
Journal:  Am J Psychiatry       Date:  1982-04       Impact factor: 18.112

View more
  17 in total

Review 1.  Delirium in elderly people.

Authors:  Sharon K Inouye; Rudi G J Westendorp; Jane S Saczynski
Journal:  Lancet       Date:  2013-08-28       Impact factor: 79.321

Review 2.  Drug-induced cognition disorders in the elderly: incidence, prevention and management.

Authors:  S L Gray; K V Lai; E B Larson
Journal:  Drug Saf       Date:  1999-08       Impact factor: 5.606

3.  Decrease of antiparkinsonian drugs before start of an antipsychotic in patients on levodopa treatment?

Authors:  David A M C van de Vijver; Raymund A C Roos; Paul A F Jansen; Arijan J Porsius; Anthonius de Boer
Journal:  Pharm World Sci       Date:  2004-10

Review 4.  State of the clinical science of perioperative brain health: report from the American Society of Anesthesiologists Brain Health Initiative Summit 2018.

Authors:  Elizabeth Mahanna-Gabrielli; Katie J Schenning; Lars I Eriksson; Jeffrey N Browndyke; Clinton B Wright; Deborah J Culley; Lis Evered; David A Scott; Nae Yah Wang; Charles H Brown; Esther Oh; Patrick Purdon; Sharon Inouye; Miles Berger; Robert A Whittington; Catherine C Price; Stacie Deiner
Journal:  Br J Anaesth       Date:  2019-08-19       Impact factor: 9.166

5.  Intrathecal pramipexole and selegiline for sensory and motor block in rats.

Authors:  Chun-Chang Yeh; An-Kuo Chou; Yu-Wen Chen; Ching-Hsia Hung; Chong-Chi Chiu; Jhi-Joung Wang; Guan-Cheng Zhu
Journal:  Pharmacol Rep       Date:  2022-05-13       Impact factor: 3.024

6.  Use of latent variable modeling to delineate psychiatric and cognitive profiles in Parkinson disease.

Authors:  Shahrzad Mavandadi; Sarra Nazem; Thomas R Ten Have; Andrew D Siderowf; John E Duda; Matthew B Stern; Daniel Weintraub
Journal:  Am J Geriatr Psychiatry       Date:  2009-11       Impact factor: 4.105

Review 7.  Delirium in elderly adults: diagnosis, prevention and treatment.

Authors:  Tamara G Fong; Samir R Tulebaev; Sharon K Inouye
Journal:  Nat Rev Neurol       Date:  2009-04       Impact factor: 42.937

8.  Cognitive toxicity of drugs used in the elderly.

Authors:  L L von Moltke; D J Greenblatt; M K Romach; E M Sellers
Journal:  Dialogues Clin Neurosci       Date:  2001-09       Impact factor: 5.986

9.  Evidence-based guidelines for treating bipolar disorder: Revised third edition recommendations from the British Association for Psychopharmacology.

Authors:  G M Goodwin; P M Haddad; I N Ferrier; J K Aronson; Trh Barnes; A Cipriani; D R Coghill; S Fazel; J R Geddes; H Grunze; E A Holmes; O Howes; S Hudson; N Hunt; I Jones; I C Macmillan; H McAllister-Williams; D R Miklowitz; R Morriss; M Munafò; C Paton; B J Saharkian; Kea Saunders; Jma Sinclair; D Taylor; E Vieta; A H Young
Journal:  J Psychopharmacol       Date:  2016-03-15       Impact factor: 4.153

Review 10.  Unravelling the pathophysiology of delirium: a focus on the role of aberrant stress responses.

Authors:  Alasdair M J Maclullich; Karen J Ferguson; Thomas Miller; Sophia E J A de Rooij; Colm Cunningham
Journal:  J Psychosom Res       Date:  2008-09       Impact factor: 3.006

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.